TY - JOUR
T1 - Polymeric Prodrugs Targeting Polyamine Metabolism Inhibit Zika Virus Replication
AU - Routhu, Nanda Kishore
AU - Xie, Ying
AU - Dunworth, Matthew
AU - Casero, Robert A.
AU - Oupicky, David
AU - Byrareddy, Siddappa N.
N1 - Funding Information:
This work is supported in part by National Institutes of Health R01AI113883 and Nebraska Neuroscience Alliance Endowed Fund Award to S.N.B. We thank Dr. Dave for critical reading and Robin Taylor for editorial assistance. We thank Dr. Marton for providing PG11047. We thank Dr. Myung Hee Park (NIH/NIDCR) and Dr. Robert A. Casero, Jr., (JHSM) for kindly providing pCMV7.1 3X FLAG/SAT1 and phCMV3 HA c-terminal tagged SMOX vectors, respectively. We thank Dr. Gmeiner, Wake Forest School of Medicine, for providing SNB-19 cells.
Publisher Copyright:
© 2018 American Chemical Society.
PY - 2018/9/4
Y1 - 2018/9/4
N2 - The Zika virus (ZIKV) is primarily transmitted via an infected mosquito bite, during sexual intercourse, or in utero mother to child transmission. When a fetus is infected, both neurological malformations and deficits in brain development are frequently manifested. As such, there is a need for vaccines or drugs that may be used to cure ZIKV infections. Metabolic pathways play a crucial role in cell differentiation and development. More importantly, polyamines play a key role in replication and translation of several RNA viruses, including ZIKV, Dengue virus, and Chikungunya virus. Here, we present polyamine analogues (BENSpm and PG11047) and their corresponding polymer prodrug derivatives for inhibiting ZIKV infection by intersecting with polyamine catabolism pathways. We tested the compounds against ZIKV African (MR766) and Asian (PRVABC59) strains in human kidney epithelial (Vero) and glioblastoma derived (SNB-19) cell lines. Our results demonstrate potent inhibition of ZIKV viral replication in both cell lines tested. This antiviral effect was mediated by the upregulation of two polyamine catabolic enzymes, spermine oxidase, and spermidine (SMOX)/spermine N1-acetyltransferase (SAT1) as apparent reduction of the ZIKV infection following heterologous expression of SMOX and SAT1. On the basis of these observations, we infer potential use of these polyamine analogues to treat ZIKV infections.
AB - The Zika virus (ZIKV) is primarily transmitted via an infected mosquito bite, during sexual intercourse, or in utero mother to child transmission. When a fetus is infected, both neurological malformations and deficits in brain development are frequently manifested. As such, there is a need for vaccines or drugs that may be used to cure ZIKV infections. Metabolic pathways play a crucial role in cell differentiation and development. More importantly, polyamines play a key role in replication and translation of several RNA viruses, including ZIKV, Dengue virus, and Chikungunya virus. Here, we present polyamine analogues (BENSpm and PG11047) and their corresponding polymer prodrug derivatives for inhibiting ZIKV infection by intersecting with polyamine catabolism pathways. We tested the compounds against ZIKV African (MR766) and Asian (PRVABC59) strains in human kidney epithelial (Vero) and glioblastoma derived (SNB-19) cell lines. Our results demonstrate potent inhibition of ZIKV viral replication in both cell lines tested. This antiviral effect was mediated by the upregulation of two polyamine catabolic enzymes, spermine oxidase, and spermidine (SMOX)/spermine N1-acetyltransferase (SAT1) as apparent reduction of the ZIKV infection following heterologous expression of SMOX and SAT1. On the basis of these observations, we infer potential use of these polyamine analogues to treat ZIKV infections.
KW - SAT1
KW - SMOX
KW - Zika virus
KW - bisethylnorspermine
KW - polyamine metabolism
KW - polyamines
KW - prodrugs
KW - virus replication
UR - http://www.scopus.com/inward/record.url?scp=85050818783&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050818783&partnerID=8YFLogxK
U2 - 10.1021/acs.molpharmaceut.8b00068
DO - 10.1021/acs.molpharmaceut.8b00068
M3 - Article
C2 - 30040423
AN - SCOPUS:85050818783
SN - 1543-8384
VL - 15
SP - 4284
EP - 4295
JO - Molecular Pharmaceutics
JF - Molecular Pharmaceutics
IS - 9
ER -